Abstract
In an asymptomatic 77-yearold woman, former 55 packyears smoker, a routine X-ray showed a 45-mm superior left lobe lesion. A chest CT scan confirmed a 36-mm superior left lobe lesion and an aortic-pulmonary lymph node enlargement measuring 42 mm, suspicious for neoplasia. A PET-CT scan showed an elevated uptake in the primary lesion, in the aortic-pulmonary lymph node, and in the left hilar lymph node with a standardized uptake value - 40 and 4.3, respectively. CT-guided lung biopsy showed a lung squamous cell carcinoma. An endobronchial ultrasound-guided transbronchial needle aspiration for lymph-node staging was negative for lymph node spread. Brain MRI was negative. Final staging was determined to be a IIIA (T2bN2) squamous cell carcinoma of the lung.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Betacoronavirus
-
COVID-19
-
Carboplatin / administration & dosage
-
Carcinoma, Squamous Cell / diagnostic imaging
-
Carcinoma, Squamous Cell / therapy*
-
Chemoradiotherapy
-
Consolidation Chemotherapy
-
Coronavirus Infections / diagnosis*
-
Diagnosis, Differential
-
Female
-
Humans
-
Lung / diagnostic imaging
-
Lung Neoplasms / diagnostic imaging
-
Lung Neoplasms / therapy*
-
Paclitaxel / administration & dosage
-
Pandemics
-
Pneumonia / chemically induced
-
Pneumonia / diagnosis*
-
Pneumonia, Viral / diagnosis*
-
SARS-CoV-2
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents, Immunological
-
durvalumab
-
Carboplatin
-
Paclitaxel